טוען...
Targets for Ibrutinib Beyond B Cell Malignancies
Ibrutinib (Imbruvica(™)) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicin...
שמור ב:
| הוצא לאור ב: | Scand J Immunol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347933/ https://ncbi.nlm.nih.gov/pubmed/26111359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/sji.12333 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|